About Aegerion Pharmaceuticals (NASDAQ:AEGR)
Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).
Industry, Sector and Symbol:
- Industry: Pharmaceuticals
- Sub-Industry: Biotechnology
- Sector: Pharmaceuticals - NEC
- Symbol: NASDAQ:AEGR
- CUSIP: 00767E10
- Web: www.aegerion.com
- Debt-to-Equity Ratio: -19.22%
- Current Ratio: 1.02%
- Quick Ratio: 0.67%
- Trailing EPS: ($5.97)
- Net Margins: -75.07%
- Return on Assets: -29.21%
- Employees: 318
- Outstanding Shares: 29,540,000
Frequently Asked Questions for Aegerion Pharmaceuticals (NASDAQ:AEGR)
What is Aegerion Pharmaceuticals' stock symbol?
Aegerion Pharmaceuticals trades on the NASDAQ under the ticker symbol "AEGR."
How were Aegerion Pharmaceuticals' earnings last quarter?
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) issued its earnings results on Monday, May, 16th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.58) by $1.14. The biopharmaceutical company earned $35.70 million during the quarter, compared to analyst estimates of $43 million. Aegerion Pharmaceuticals's revenue was down 39.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.55) EPS. View Aegerion Pharmaceuticals' Earnings History.
Where is Aegerion Pharmaceuticals' stock going? Where will Aegerion Pharmaceuticals' stock price be in 2017?
1 equities research analysts have issued 1 year price targets for Aegerion Pharmaceuticals' shares. Their forecasts range from $1.50 to $1.50. On average, they anticipate Aegerion Pharmaceuticals' stock price to reach $1.50 in the next twelve months. View Analyst Ratings for Aegerion Pharmaceuticals.
Who are some of Aegerion Pharmaceuticals' key competitors?
Some companies that are related to Aegerion Pharmaceuticals include Aralez Pharmaceuticals (ARLZ), Diurnal Group PLC (DNL), BioLife Solutions (BLFS), Innocoll Holdings PLC (INNL), Sophiris Bio (SPHS), Female Health Company (The) (VERU), Juniper Pharmaceuticals (JNP), SCYNEXIS (SCYX), Histogenics Corporation (HSGX), Amryt Pharma PLC (AMYT), Evoke Pharma (EVOK), Pernix Therapeutics Holdings (PTX), Intellipharmaceutics International (IPCI), Azurrx Biopharm (AZRX), Concordia International Corp. (CXRX), Apricus Biosciences (APRI), Cellectar Biosciences (CLRB) and Eyegate Pharmaceuticals (EYEG).
How do I buy Aegerion Pharmaceuticals stock?
Shares of Aegerion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aegerion Pharmaceuticals' stock price today?
One share of Aegerion Pharmaceuticals stock can currently be purchased for approximately $1.97.
How big of a company is Aegerion Pharmaceuticals?
Aegerion Pharmaceuticals has a market capitalization of $56.69 million. Aegerion Pharmaceuticals employs 318 workers across the globe.
How can I contact Aegerion Pharmaceuticals?
Aegerion Pharmaceuticals' mailing address is 1 Main St Ste 800, CAMBRIDGE, MA 02142-1531, United States. The biopharmaceutical company can be reached via phone at +1-617-5007867.
MarketBeat Community Rating for Aegerion Pharmaceuticals (NASDAQ AEGR)MarketBeat's community ratings are surveys of what our community members think about Aegerion Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Aegerion Pharmaceuticals (NASDAQ:AEGR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 0 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||$1.50 (23.86% downside)|
Consensus Price Target History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Analysts' Ratings History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
(Data available from 11/18/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/30/2016||Cowen and Company||Reiterated Rating||Hold||$1.50||N/A|
|11/11/2016||J P Morgan Chase & Co||Initiated Coverage||Hold||N/A|
|5/17/2016||Leerink Swann||Boost Price Target||Outperform||$6.00 -> $15.00||N/A|
|2/12/2016||Bank of America Corporation||Downgrade||Neutral -> Underperform||$6.00||N/A|
|12/21/2015||Guggenheim||Upgrade||Sell -> Buy||$7.00 -> $13.00||N/A|
Earnings History and Estimates Chart for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Earnings History by Quarter for Aegerion Pharmaceuticals (NASDAQ AEGR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/16/2016||Q1||($0.58)||($1.72)||$43.00 million||$35.70 million||View||Listen|
|2/25/2016||Q4||($0.89)||($0.69)||$47.74 million||$49.00 million||View||Listen|
|11/9/2015||Q315||($0.42)||($0.34)||$59.72 million||$67.30 million||View||N/A|
|8/5/2015||Q2||($0.27)||($0.01)||$58.98 million||$64.20 million||View||N/A|
|10/30/2014||Q314||($0.18)||($0.12)||$48.60 million||$43.70 million||View||N/A|
|7/29/2014||Q214||($0.41)||($0.33)||$35.40 million||$36.00 million||View||Listen|
|5/6/2014||Q1||($0.35)||($0.54)||$33.58 million||$27.00 million||View||Listen|
|2/26/2014||Q413||($0.30)||($0.14)||$24.51 million||$24.50 million||View||Listen|
|10/29/2013||Q313||($0.50)||($0.43)||$13.07 million||$16.30 million||View||N/A|
|7/30/2013||Q2 2013||($0.62)||($0.66)||$4.27 million||$6.50 million||View||N/A|
Earnings Estimates for Aegerion Pharmaceuticals (NASDAQ:AEGR)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Aegerion Pharmaceuticals (NASDAQ AEGR)
Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 84.87%
Insider Trades by Quarter for Aegerion Pharmaceuticals (NASDAQ AEGR)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/13/2016||Healthcare Master Fun Broadfin||Major Shareholder||Buy||75,000||$1.75||$131,250.00|| |
|9/12/2016||Healthcare Master Fun Broadfin||Major Shareholder||Buy||276,000||$1.66||$458,160.00|| |
|8/19/2014||Mark J Fitzpatrick||CFO||Buy||1,150||$30.64||$35,236.00|| |
|7/31/2014||Marc D Beer||CEO||Buy||10,000||$33.65||$336,500.00|| |
|6/3/2014||Marc D Beer||CEO||Buy||10,000||$30.12||$301,200.00|| |
|5/27/2014||Marc D Beer||CEO||Buy||10,000||$31.59||$315,900.00|| |
|5/20/2014||Marc Beer||CEO||Buy||10,000||$30.53||$305,300.00|| |
|5/8/2014||Anne Vanlent||Director||Buy||4,000||$33.78||$135,120.00|| |
|5/8/2014||Marc Beer||CEO||Buy||30,000||$35.31||$1,059,300.00|| |
|4/30/2014||Craig Fraser||Insider||Sell||2,250||$43.55||$97,987.50|| |
|3/31/2014||Craig Fraser||Insider||Sell||2,250||$46.20||$103,950.00|| |
|3/14/2014||Mark Sumeray||Insider||Sell||2,000||$51.34||$102,680.00|| |
|2/11/2014||Craig Fraser||Insider||Sell||2,250||$67.00||$150,750.00|| |
|12/16/2013||Mark Sumeray||Insider||Sell||2,000||$66.34||$132,680.00|| |
|10/30/2013||Marc D Beer||CEO||Sell||40,000||$87.79||$3,511,600.00|| |
|10/29/2013||Sandford D Smith||Director||Sell||2,502||$95.00||$237,690.00|| |
|10/15/2013||Mark Sumeray||Insider||Sell||2,000||$80.33||$160,660.00|| |
|10/7/2013||Mark Sumeray||Insider||Sell||3,500||$93.17||$326,095.00|| |
|9/16/2013||Mark Sumeray||Insider||Sell||2,000||$89.77||$179,540.00|| |
|9/5/2013||Perceptive Advisors Llc||Major Shareholder||Sell||750,000||$89.20||$66,900,000.00|| |
|8/21/2013||David Scheer||Director||Sell||20,000||$84.58||$1,691,600.00|| |
|8/16/2013||Mark Sumeray||Insider||Sell||2,000||$88.71||$177,420.00|| |
|8/15/2013||Marc Beer||CEO||Sell||60,000||$88.54||$5,312,400.00|| |
|8/14/2013||Mark Fitzpatrick||CFO||Sell||7,500||$93.44||$700,800.00|| |
|8/12/2013||Sandford Smith||Director||Sell||10,000||$92.32||$923,200.00|| |
|7/15/2013||Mark Sumeray||Insider||Sell||2,000||$78.77||$157,540.00|| |
|6/17/2013||Mark Sumeray||Insider||Sell||6,000||$65.27||$391,620.00|| |
|5/15/2013||Mark Sumeray||Insider||Sell||6,000||$47.32||$283,920.00|| |
|2/1/2013||Perceptive Advisors Llc||Major Shareholder||Buy||50,000||$27.79||$1,389,500.00|| |
|1/18/2013||Perceptive Advisors Llc||Major Shareholder||Buy||50,000||$27.62||$1,381,000.00|| |
|1/17/2013||Perceptive Advisors Llc||Major Shareholder||Buy||50,000||$26.73||$1,336,500.00|| |
|1/11/2013||Perceptive Advisors Llc||Major Shareholder||Buy||475,000||$27.07||$12,858,250.00|| |
|12/4/2012||Perceptive Advisors Llc||Major Shareholder||Buy||20,000||$21.27||$425,400.00|| |
|11/29/2012||Perceptive Advisors Llc||Major Shareholder||Buy||30,000||$22.71||$681,300.00|| |
|11/28/2012||Perceptive Advisors Llc||Major Shareholder||Buy||150,000||$21.25||$3,187,500.00|| |
Headline Trends for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Latest Headlines for Aegerion Pharmaceuticals (NASDAQ AEGR)
Aegerion Pharmaceuticals (NASDAQ AEGR) Chart for Saturday, November, 18, 2017